- Neuland Laboratories has appointed Saharsh Davuluri as CEO and Managing Director, effective immediately.
- The company reported that its contract services revenues have tripled over the past three years as it expands its CDMO capabilities.
Neuland Laboratories has appointed Saharsh Davuluri as Chief Executive Officer and Managing Director, effective immediately, as the company advances its contract manufacturing and CDMO growth strategy. He succeeds Sucheth Davuluri, who will transition to the role of Executive Vice Chairman.
Saharsh Davuluri has been with the company for more than 18 years and has played a role in shaping its focus on new chemical entity (NCE) drug substance development. The company has expanded its presence in API process development and commercial manufacturing, supported by demand from global innovator companies.
Neuland Laboratories stated that its contract services revenues have tripled over the past three years. The company has secured multiple commercial manufacturing contracts and continues to focus on complex APIs and peptides. It operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1,218 KL of installed capacity.
The company is pursuing further expansion, including a four-phase increase in commercial peptide capacity and additional investment in process development capabilities. It also indicated the potential to secure additional commercial NCE contracts over the next one to two years, subject to customer approvals.
“It’s an incredibly exciting time for the wider CDMO sector, and for Neuland in particular, as global innovators increasingly come to us with their most complex chemistries and scale-up challenges.”
Saharsh Davuluri
